Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
eqs_en 
0 17.03.22
Kuros Biosciences reports results for the full year 2021
Kuros Biosciences reports results for the full year 2021
Kuros Biosciences reports results for the full year 2021
eqs_en 
0 16.03.22
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
eqs_en 
0 15.03.22
Evolva grew product-related revenue by 40% in 2021
Evolva grew product-related revenue by 40% in 2021
Evolva grew product-related revenue by 40% in 2021
eqs_en 
0 10.03.22
Judgment in patent infringement case - Advanced Bionics files appeal
Judgment in patent infringement case - Advanced Bionics files appeal
Judgment in patent infringement case - Advanced Bionics files appeal
eqs_en 
0 08.03.22
Urteil in Patentverletzungsprozess -  Advanced Bionics legt Berufung ein
Urteil in Patentverletzungsprozess -  Advanced Bionics legt Berufung ein
Urteil in Patentverletzungsprozess -  Advanced Bionics legt Berufung ein
eqs_de 
0 08.03.22
2021 financial year: Sharp rise in sales and profits
2021 financial year: Sharp rise in sales and profits
2021 financial year: Sharp rise in sales and profits
eqs_en 
0 04.03.22
Geschäftsjahr 2021: Markante Umsatz- und Gewinnsteigerung
Geschäftsjahr 2021: Markante Umsatz- und Gewinnsteigerung
Geschäftsjahr 2021: Markante Umsatz- und Gewinnsteigerung
eqs_de 
0 04.03.22
Sonova schliesst Übernahme der Sennheiser Consumer Division ab und schafft neues Geschäftsfeld
Sonova schliesst Übernahme der Sennheiser Consumer Division ab und schafft neues Geschäftsfeld
Sonova schliesst Übernahme der Sennheiser Consumer Division ab und schafft neues Geschäftsfeld
eqs_de 
0 01.03.22
Sonova completes acquisition of the Sennheiser Consumer Division and forms a new business
Sonova completes acquisition of the Sennheiser Consumer Division and forms a new business
Sonova completes acquisition of the Sennheiser Consumer Division and forms a new business
eqs_en 
0 01.03.22
Sonova schliesst Übernahme von Alpaca Audiology ab
Sonova schliesst Übernahme von Alpaca Audiology ab
Sonova schliesst Übernahme von Alpaca Audiology ab
eqs_de 
0 01.03.22
Sonova completes acquisition of Alpaca Audiology
Sonova completes acquisition of Alpaca Audiology
Sonova completes acquisition of Alpaca Audiology
eqs_en 
0 01.03.22
Carsten Däweritz remains CFO of Evolva
Carsten Däweritz remains CFO of Evolva
Carsten Däweritz remains CFO of Evolva
eqs_en 
0 28.02.22
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
eqs_de 
0 18.02.22
DGAP-News: BB Biotech AG publishes its 2021 annual report
DGAP-News: BB Biotech AG publishes its 2021 annual report
DGAP-News: BB Biotech AG publishes its 2021 annual report
eqs_en 
0 18.02.22
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
eqs_en 
0 16.02.22
Straumann Group erzielt einen Umsatz von über CHF 2 Milliarden
Straumann Group erzielt einen Umsatz von über CHF 2 Milliarden
Straumann Group erzielt einen Umsatz von über CHF 2 Milliarden
eqs_de 
0 15.02.22
Straumann Group reports revenue exceeding CHF 2 billion
Straumann Group reports revenue exceeding CHF 2 billion
Straumann Group reports revenue exceeding CHF 2 billion
eqs_en 
0 15.02.22
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
eqs_en 
0 08.02.22
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
eqs_en 
0 08.02.22
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
eqs_de 
0 04.02.22
Invitation: Straumann Group 2021 full-year financial results webcast
Invitation: Straumann Group 2021 full-year financial results webcast
Invitation: Straumann Group 2021 full-year financial results webcast
eqs_en 
0 04.02.22
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
eqs_en 
0 03.02.22
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
eqs_en 
0 02.02.22
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
eqs_en 
0 01.02.22